Aktualitātes

Inese Erdmane, Chairwoman of the Board at LZVO share insights of the Latvian medicine’s verification process with Dansk Medicin Verifikation Organisation Newsletter.

In order to be able to prepare the draft budget of the Latvian Medicines Verification Organisation (LZVO) for 2022 and calculate the annual fee of the MAH, we invite all MAHs to immediately update the information in accordance with Article 4.2 of the Cooperation Agreement.

EMVO informs, that prototype and first phase of development for AMS HUB has been completed. AMS HUB solution is currently under system test by provider (started at September 17). Next milestone would be production pilot phase – October 4.

The Latvian Medicines Verification Organisation (LZVO) reminds that all LZVS end users have certain obligations to be fulfilled in the daily verification process of medicines and in cases where an alert is generated in the system.

To guarantee the safety and authenticity of medicines to patients, in the first half of 2021, 12 million packages of medicines were verified in the system and reached consumers in Latvia, according to the Latvian Medicines Verification Organization (LZVO) data

The Latvian Medicines Verification System (LZVS) has successfully passed all compatibility tests so that the Latvian national system is prepared for European Medicines Verification System (EU Hub) updates / system release 1.9. LZVS is ready to work without interruption and restriction